Tumor Infiltrating Lymphocytes Adjuvant Therapy of Melanoma

Melanoma Clinical Trial

— TIL  

Official title:

TIL (Tumor Infiltrating Lymphocytes) and IL2 (Interleukin 2) Versus Abstention as Adjuvant Treatment in Melanoma With Only One Invaded Lymphnode After Lymphnodes Excision

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00200577
• Other study ID #: BRD/04/01-D
• Status: Completed
• Phase: Phase 3
• First received: September 12, 2005
• Last updated: May 31, 2017
• Start date: May 2005
• Est. completion date: March 2012

Study information

• Verified date: May 2017
• Source: Nantes University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this multicentric Phase III study is to confirm the results of the phase I-II study (Dreno B & Al. Cancer Immunol Immunother 2002; 51: 539-456) which demonstrated the preventive effect of a treatment by TIL (Tumor Infiltrating Lymphocytes) combined with IL2 (Interleukin 2; low dose injected subcutaneously) on the metastatic relapse in the stage III melanoma patients with only one invaded lymphnode.

Description:

In this open, multicentric (Grenoble, Montpellier, Nantes, Angers, Caen, Le Mans, Poitiers, Rennes, Tours) randomized study, selected patients with only one invaded lymphnode confirmed by anatomopathological exam will be randomized to one of the following arms: 1-Control group: patients of this group will not receive any treatment and will have the same clinical follow-up as the treated group. 2- TIL-IL2 group: treated patients will receive two injections of TIL combined with IL2. Tumor Infiltrating Lymphocytes will be obtained from a small piece of tumour tissue removed from the invaded lymphnode after surgery. TIL will be grown in larger number in laboratory during 6 weeks. Patients randomized in treatment arm will receive two injection of TIL (the first about 6 and the second about 10 weeks post-surgery). Administration of TIL will be combined with a low dose of IL2 (6 million U.I. per day) injected subcutaneously from J1 to J5 and J8 to J12 following the day of TIL infusion. The same dose and duration of IL2 treatment will be used for the second injection of TIL performed one month later. After 2 months adjuvant therapy, patients received no other treatment. Only a regular follow-up was performed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 70
• Est. completion date: March 2012
• Est. primary completion date: March 2012
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 75 Years

Eligibility

Inclusion Criteria:

• Melanoma stage III (regional lymph node recurrence). Will be selected the patients with only one invaded lymph node confirmed by anatomopathological exam after lymph nodes excision.

• Absence of visceral metastases verified by physical examination, chest radiography, liver echography and brain-chest-liver CT-Scan.

• Age < 75 years, both genders

• ECOG 0-2, Karnofsky > 80%.

• Negative pregnancy test performed at the screening visit for fertile women.

• The potentially fertile women must use an oral contraception or an intra-uterine device (IUD) until three months following the last injection of the study treatment.

• The patients must have fully recovered from surgery.

• HIV 1/2: The patients must be negative for antibodies HIV 1 and HIV 2 and for Ag P24 or DGV HIV.

• HBV: The patients must be negative for the antigen, but can be positive for the antibodies but with a negative DNA PCR.

• HCV: The patients must be negative for the antibodies.

• HTLV ½: The patients must be negative for the antibodies.

• Following laboratory results:

• Hemoglobin: = 10 g/dl

• WBC: = 4000/µl

• Lymphocytes: = 700/µl

• Platelet count: = 100.000/µl

• Serum creatinine: < 2.0 mg/dl or £ 177 mmol/l

• Serum Bilirubin: < 2.0 mg/dl or £ 34.2 mmol/l

• ASAT and ALAT: < 2.5 x the upper limit of normal.

Exclusion criteria:

• Patient with more than one invaded lymph node confirmed by anatomopathological exam.

• Presence of melanoma metastases discovered by clinical or radiological examination at the screening visit.

• Patients must not have received any Chemotherapy, immunotherapy or radiotherapy within the preceding 4 weeks (6 weeks since prior nitrosurea and mitomycin C therapies).

• Presence of cardiac affections (congestive cardiac insufficiency, coronaropathy, not controlled HTA).

• Any serious active medical illnesses, for example: Active systemic infections requiring of antibiotics, coagulation disorders or any other condition which requires concomitant medications not allowed during this study.

• Presence of the second active cancer other than surgically cured non-melanoma skin cancer or cervical carcinoma in-situ.

• Any affection requiring a systemic corticotherapy or a treatment by Interferon A.

• Any active auto-immune disease including the insulin-dependent diabetes or a immunodeficiency. The vitiligo is not an exclusion criteria.

• Thyroid dysfunction not responsive to therapy.

• Positive Serology for HIV, HVB, HVC or HTLV1/2.

• Woman pregnant or nursing or without an effective contraception.

• Incapacity to give written consent.

Related Conditions & MeSH terms

• Melanoma

Intervention

Drug:
• TIL + IL2
Patients are treated with 2 injections Of TIL (1st injection M1 and the second M2)The received concomitant IL2 at M1 and M2 on days Jo (injection TIL) to J5 and J8 to J12

Locations

Country	Name	City	State
France	CHU Angers	Angers
France	CHU Caen	Caen
France	Grenoble University Hospital	Grenoble
France	CH Le Mans	Le Mans
France	Montpellier University Hospital	Montpellier
France	Nantes University Hospital	Nantes
France	CHU Poitiers	Poitiers
France	CHU Rennes	Rennes
France	CHRU Tours	Tours

Sponsors (1)

Lead Sponsor	Collaborator
Nantes University Hospital

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Determination of the duration of the relapse-free interval.		5 years
Primary	Physical examination, every 2 months until M18 then every 3 months until M36 then every 4 months up to 5 years, then once per year with a clinical examination only.		every 2 months until M18then every 3 months until M36 then every 4 months up to 5 years
Primary	Abdominal echography will be performed at the screening visit, M4, M8, M12 and then every 6 months until 5ans.		M4, M8, M12 and then every 6 months until 5ans.
Primary	CT-Scan will be performed before the first administration of study treatment (at the time of screening visit), every 6 months during 2 years and then every years up to 5 years.		every 6 months during 2 years and then every years up to 5 years.
Secondary	Determine of overall survival		5 years
Secondary	To define safety and toxicity of TIL/IL2 treatment		5 years
Secondary	Evaluation of immunological responses		M0, J56, M12
Secondary	Analysis of the clinical, biological and histological factors on the survival of the patients		at inclusion and each month